Amarin Corp plc (AMRN) Misses Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Price: $14.15 +0.64%
Financial Fact:
Net and comprehensive loss: -15.77M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Net and comprehensive loss: -15.77M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Amarin Corp plc (NASDAQ: AMRN) reported Q3 EPS of ($0.17), $0.04 worse than the analyst estimate of ($0.13).
Recognized $14.1 million in product revenue from Vascepa® (icosapent ethyl) sales in Q3 2014 compared to $12.6 million in Q2 2014 and $8.4 million in Q3 2013, an increase of 12% and 68%, respectively
For earnings history and earnings-related data on Amarin Corp plc (AMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- SuperCom (SPCB) Tops Q3 EPS by 43c
- Benchmark Reiterates Buy Rating on NANO Nuclear Energy (NNE)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
